In a Lewis lung cancer tumor model, they found that vaccines with these peptides significantly inhibited tumor growth by activating ARG2-specific T cell response, which may constitute a future potential for a new therapeutic candidate in immunotherapy [154]. Here, ARG2 is linked to neoplasm.